17:24 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Inovio reports interim Phase I data for HBV candidate

Inovio Pharmaceuticals Inc. (NASDAQ:INO) reported interim data from a Phase I trial showing that HBV candidate INO-1800 was well tolerated and generated virus-specific T cells, including CD8+ killer T cells. The open-label, dose-escalation, international trial enrolled...
23:53 , Feb 22, 2018 |  BC Innovations  |  Product R&D

Shooting for the universe

CureVac AG is bringing a new modality to the race for a universal flu vaccine with an mRNA program backed by a grant from the Bill & Melinda Gates Foundation. While the company believes its...
22:53 , Jan 5, 2018 |  BC Week In Review  |  Company News

Inovio, ApolloBio amend VGX-3100 deal

Inovio Pharmaceuticals Inc. (NASDAQ:INO) and ApolloBio Corp. (NEEQ:430187) amended a deal granting ApolloBio exclusive rights to develop and commercialize VGX-3100 in Taiwan and China, including Hong Kong and Macau, to treat or prevent pre-cancerous infections...
23:41 , Dec 12, 2017 |  BC Extra  |  Company News

Management tracks: Achaogen, Minerva

Antibacterial company Achaogen Inc. (NASDAQ:AKAO) said Kenneth Hillan will step down as CEO, effective Jan. 1. He will remain president and president of R&D. Blake Wise, who has served as president and COO, will become...
23:29 , Oct 6, 2017 |  BioCentury  |  Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
10:21 , Aug 24, 2017 |  BC Innovations  |  Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...
20:33 , Jul 21, 2017 |  BC Week In Review  |  Financial News

Inovio raises $75M in follow-on

On July 19, Inovio Pharmaceuticals Inc. (NASDAQ:INO) raised $75 million through the sale of 12.5 million shares at $6 in a follow-on underwritten by Citigroup, Piper Jaffray, RBC Capital Markets, H.C. Wainwright, Maxim Group, Aegis...
23:35 , Jul 20, 2017 |  BC Extra  |  Financial News

Inovio raises $75M in follow-on

Inovio Pharmaceuticals Inc. (NASDAQ:INO) raised $75 million through the sale of 12.5 million shares at $6.00 in a follow-on underwritten by Citigroup, Piper Jaffray, RBC Capital Markets, H.C. Wainwright, Maxim Group, Aegis Capital, and the...
20:19 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Inovio resumes VGX-3100 HPV cancer program

Inovio Pharmaceuticals Inc. (NASDAQ:INO) said FDA lifted a clinical hold on its Phase III program of VGX-3100 to treat cervical dysplasia caused by HPV. The company plans to immediately begin a pair of Phase III...
19:54 , Jun 9, 2017 |  BC Week In Review  |  Company News

Inovio running PHI/II trial with Genentech PD-L1 mAb

Inovio Pharmaceuticals Inc. (NASDAQ:INO) will conduct a Phase Ib/II trial evaluating its INO-5401 and INO-9012 in combination with PD-L1 mAb Tecentriq atezolizumab from Genentech Inc. (South San Francisco, Calif.) to treat advanced unresectable or metastatic...